Novo Nordisk lowers cost of Ozempic to $499 per month for self-paying patients

Novo Nordisk has launched a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved Ozempic (semaglutide) for $499 per month, as part of the company's ongoing effort to explore new collaborations and approaches to improving access to authentic semaglutide medicines.

This offer is available through multiple platforms to eligible patients with a prescription for Ozempic and aims to assist type 2 diabetes patients who may potentially face prices at or above wholesale cost that are uninsured or choose to self-pay.

"Improving access to our authentic FDA-approved treatments is central to our mission at Novo Nordisk. While Ozempic is well covered in the US, let's not forget that there are some patients who pay out-of-pocket for this vital medicine. We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. "This is why we felt it was important to make Ozempic, the GLP-1 with the broadest range of FDA-approved indications for adults with type 2. "

The offer is available through multiple platforms so that patients with a prescription for real, FDA-approved Ozempic can access it in the way that suits them best. In addition, Novo Nordisk is collaborating with GoodRx, a platform for medication savings in the US, to offer both Wegovy (for adults with obesity) and Ozempic (for adults with type 2 diabetes) at $499 per month through the GoodRx platform, making this price available to eligible self-paying patients at more than 70,000 pharmacies nationwide.

Novo Nordisk is continuing to take multiple proactive measures to keep patients aware of potentially unsafe and unapproved knockoff alternatives and informed of how to access authentic, FDA-approved medicines.